Patterns in detection of recurrence among patients treated for breast cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e14020-e14020
Author(s):  
Lena Saltbæk ◽  
Trine Allerslev Horsbøll ◽  
Birgitte Vrou Offersen ◽  
Michael Andersson ◽  
Anne Sofie Friberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Outpatient Visit ◽  
Recurrent Breast Cancer ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Duration Of Symptoms ◽  
Cancer Group ◽  
Outpatient Visits ◽  
Breast Cancer Group

e14020 Background: Follow-up programs for breast cancer should according to ASCO and ESMO consist of regular visits including anamnestic screening for symptoms of recurrence and physical examination for ten years in addition to regular mammography. Recently, the Danish guideline for follow-up after early breast cancer was revised. Today most patients are offered open access to an outpatient clinic, but no scheduled visits following the first year after surgery. This strategy has been studied in regards to psychological and health related quality of life outcomes, but not in regards to detection of recurrence and survival. The aim of this study was to quantify the recurrences detected at scheduled outpatient visits in Denmark before the implementation of revised follow-up guidelines. Furthermore, we aimed to assess whether the duration of symptoms prior to recurrence detection differed depending on type of visit when recurrence was detected. Methods: We conducted a cross-sectional study among 310 patients with recurrent breast cancer. Through medical records, we retrieved information on type of visit when recurrence was detected, localization of recurrence, symptoms reported, and duration of symptoms. Tumor characteristics were obtained from the Danish Breast Cancer Group database. Results: Among the 310 breast cancer recurrences, more than half were distant (59%), 26% were loco-regional, and 15% loco-regional and distant. Among the 199 patients still in outpatient follow-up at time of recurrence, recurrence was detected at a scheduled outpatient visit (21%), at a patient-requested extra outpatient visit (15%), by the general practitioner or other specialist (47%), or on a scheduled mammography (11%). Among patients with recurrence detected at a scheduled outpatient visit, the majority (88%) reported symptoms related to the recurrence. Patients who waited for the scheduled outpatient visit despite symptoms had a markedly longer duration of symptoms (median 21 weeks) prior to detection of recurrence than patients who requested an extra visit (median 8 weeks). Conclusions: One-fifth of recurrences among patients attending outpatient follow-up were detected at scheduled outpatient visits. The majority was symptomatic, but the patients had not altered their scheduled appointment. Whether recurrences like these will be detected in follow-up without scheduled visits is unknown. Some recurrences may be detected earlier, if patients can be educated to react on relevant symptoms, but some recurrences may be detected with further delay. Thus, more research in this area is needed.

Prevalence and Predictive Factors of Transient and Permanent Congenital Hypothyroidism in Fars Province, Iran

2021 ◽  
Author(s):  
Ashkan Habib ◽  
Alireza Shojazadeh ◽  
Mohadeseh Molayemat ◽  
Asadollah Habib ◽  
Marjan Jeddi ◽  
...  
Keyword(s):  
Incidence Rate ◽  
Congenital Hypothyroidism ◽  
Predictive Factors ◽  
Cross Sectional Study ◽  
Thyroid Stimulating Hormone ◽  
Fars Province ◽  
Venous Sampling ◽  
Cross Sectional ◽  
Outpatient Visits

Abstract Introduction: There is no data on the number as well as the prevalence of congenital hypothyroidism (CH) in the Fars province. Hence, we designed this study to analyze the latest data and the possible predictive factors on transient and permanent CH in this province.Method: This cross sectional study is based on the Fars province screening data from 2013 till 2016. A total of 294,214 newborns were screened with 938 confirmed cases of CH, which were included in this study. After recall and completion of the missing data, follow-up data for 642 CH cases with thyroid stimulating hormone (TSH) concentrations and levothyroxine doses for ten outpatient visits and final transient vs. permanent CH diagnosis were included.Results: The incidence rate was 1:313.66, and out of the 642 CH cases, 66.04% had permanent CH, while 33.96% had transient CH. TSH level trend during the outpatient visits were not statistically different between the two groups (P=0.312). A cutoff point of >2.25 levothyroxine µg/kg (sensitivity: 76.11%, specificity: 58.52%) at the third year and a TSH concentration of >43.35 mIU/L at the venous sampling (initial TSH) (sensitivity: 31.66%, specificity: 90.32%) were the predictive factors for permanent CH.Conclusion: Fars province has one of the highest incidence rate of CH in Iran. Levothyroxine dose at the 3rd year and the 1st venous TSH sample are the predictive factors for permanent CH in the Iranian population; however, TSH concentrations during follow ups are unreliable predictors.

scholarly journals Evaluation of sexual performance in women treated for breast cancer

Mastology ◽  
2020 ◽  
Vol 30 (Suppl 1) ◽  
Author(s):  
Letícia Sposito ◽  
Caroline Nakano Vitorino ◽  
Gislaine Maria Fontanetti Bortolotti ◽  
Andre Hideo Motoki ◽  
Daniel de Araújo Brito Buttros
Keyword(s):  
Breast Cancer ◽  
Stage Iv ◽  
Cross Sectional Study ◽  
Histopathological Diagnosis ◽  
Sexual Performance ◽  
Cross Sectional ◽  
Oncological Treatment ◽  
Informed Consent Form ◽  
Final Score

Objective: To assess the sexual performance (SP) pattern in women treated for breast cancer (BC). Methods: Cross-sectional study with 33 women treated for BC. We included women aged between 35 and 66 years, with histopathological diagnosis of breast cancer, who already concluded the initial oncological treatment (surgery, chemotherapy and radiotherapy), in stage IV, assisted in the Unified Health System. They signed the informed consent form. Oncological data, such as staging, type of surgery, type of adjuvant treatment and follow-up time were collected through the analysis of medical records. The women were submitted to individual interview to assess SP, and the Female Sexual Quotient (FSQ) questionnaire was applied. The FSQ is formed by 10 objective questions that score from 0 to 5 points according to the answer: never, infrequently or rarely, sometimes, nearly 50% of the time, most of the time, always. The final score is defined by the sum of points multiplied by 2, and the SP is classified as: poor (0-20), unfavorable (22-40), fair (42-60), good (62-80), and excellent (82-100). Mean/standard deviation and percentage rates were used for statistical analysis. The study was approved by the Research Ethics Committee, Plataforma Brasil/CAAE: 02241618.1.0000.5381. Results: The mean age and oncological follow-up were 55±11 years and 4.5±2 years, respectively. The most prevalent oncological data were: 35% were in stage 2; 84% were submitted to conserving surgery; 95%, to radiotherapy; 65% underwent chemotherapy; and 80% were on endocrine therapy. Regarding sexual performance, 62% spontaneously think about sex; 35% are always interested in sex; and 54% are always stimulated by the “foreplay”. During the sexual relation, 32% always get lubricated; 45% become more stimulated when the partner is aroused; 45% always relax their vagina appropriately; 45% never feel pain; 52% always get involved without distraction; 51% always reach orgasm; and 42% always wish to repeat sexual relations in the following days. After calculating the final score, the conclusion was that 6% have poor sexual performance; 20%, unfavorable; 20%, fair; 38%, good; and 16%, excellent. Conclusion: Most women treated for breast cancer present with sexual performance classified between good and excellent, according to the Female Sexual Quotient.

scholarly journals Teleoncology or telemedicine for oncology patients during the COVID-19 pandemic: the new normal for breast cancer survivors?

2020 ◽  
Vol 16 (28) ◽  
pp. 2191-2195
Author(s):  
Fatih Yildiz ◽  
Berna Oksuzoglu
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Survivors ◽  
Medical Oncology ◽  
Tertiary Care ◽  
Cross Sectional Study ◽  
Voice Call ◽  
Cross Sectional ◽  
New Era ◽  
Oncology Center

Background: Telemedicine is seen as a savior during the COVID-19 pandemic. Materials & methods: This study is a descriptive cross-sectional study conducted with cancer patients who were interviewed via telemedicine from a tertiary care comprehensive oncology center. Results: A total of 421 patients were included in the study and 118 of them (28.0%) were >65 years old. Communication was provided most frequently by voice call (n = 213; 50.5%). The majority of the patients contacted by telemedicine had breast cancer (n = 270; 64.1%). For 135 patients (32.1%) no further examination or intervention was required and the previously planned follow-up visit was postponed by the clinician. Conclusion: This study showed that telemedicine could open a new era for medical oncology specialists.

scholarly journals Concerns of young women with breast cancer and theirs partners from chemotherapy to follow-up: a cross-sectional study

2016 ◽  
Vol 27 ◽  
pp. vi513
Author(s):  
L. Vanlemmens ◽  
A. Congard ◽  
C. Duprez ◽  
A.-S. Baudry ◽  
A. Lesur ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Young Women ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional

scholarly journals Relationships between Follicle-Stimulating Hormone and Adiponectin in Postmenopausal Women

Metabolites ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. 420
Author(s):  
Wan-Yu Huang ◽  
Dar-Ren Chen ◽  
Chew-Teng Kor ◽  
Ting-Yu Chen ◽  
Po-Te Lin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Insulin Resistance ◽  
Postmenopausal Women ◽  
Follicle Stimulating Hormone ◽  
Rank Test ◽  
Model Assessment ◽  
Cross Sectional ◽  
Cancer Group ◽  
Breast Cancer Group ◽  
Stimulating Hormone

Beyond fertility, follicle-stimulating hormone (FSH) may exert action on adipocytes, which are the major source of adiponectin and leptin, linking to insulin resistance. Therefore, we evaluated the relationships between FSH and adipocyte-derived hormones. This cross-sectional study enrolled postmenopausal women aged 40–65 years. The variables measured in this study included clinical parameters, fasting levels of sex hormones, glucose, insulin, and adipokines. A total of 261 women without breast cancer, 88 women with breast cancer receiving tamoxifen, and 59 women with breast cancer receiving additional gonadotropin-releasing hormone analogs were enrolled in this study. Significant differences in the levels of adiponectin, leptin, and FSH were observed between the non-breast cancer group and the breast cancer groups. Spearman’s rank test revealed significant associations of FSH with either body mass index (BMI) or homeostatic model assessment of insulin resistance (HOMA-IR) values in the non-breast cancer group. After adjusting for BMI, age, and menopause duration, FSH levels were significantly associated with adiponectin (p < 0.001) and the leptin-to-adiponectin ratio (p = 0.008) in the non-breast cancer group, but they were only significantly associated with adiponectin (p = 0.001) in the breast cancer group receiving tamoxifen. Our data show that FSH levels are independently associated with adiponectin levels in postmenopausal women, suggesting that adiponectin may link FSH to metabolic relationships in postmenopausal female.

Sign in / Sign up

Export Citation Format

Share Document